Skip to main content

Bausch Lomb Corporation(BLCO-T)
TSX

Today's Change
Real-Time Last Update
Day Low19.92
Day High20.83
Open:20.83
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Bausch & Lomb: Stocks Analysts Recently Downgraded on TSX (BLCO)

Profile

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.